James Kihara Sells 1,332 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

Key Points

• Insider James Kihara sold 1,332 shares of ACADIA on May 4 at an average price of $21.79 for about $29,024, reducing his direct stake to 29,129 shares (a 4.37% decrease), after also selling 1,030 shares on April 7 at roughly $22.20.
• ACADIA reported a strong quarter on Feb. 26 with EPS of $1.60 (vs. $0.12 expected) and $298M revenue, the stock trades near $22.35 with a $3.83B market cap, and analysts hold a consensus “Moderate Buy” with an average target of $31.21.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 1,332 shares of the company's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $29,024.28. Following the completion of the transaction, the insider directly owned 29,129 shares of the company's stock, valued at approximately $634,720.91. This trade represents a 4.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

James Kihara also recently made the following trade(s):

• On Tuesday, April 7th, James Kihara sold 1,030 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $22.20, for a total value of $22,866.00.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD traded up $0.16 during mid-day trading on Tuesday, reaching $22.35. The company had a trading volume of 1,030,907 shares, compared to its average volume of 1,677,688. ACADIA Pharmaceuticals Inc. has a twelve month low of $14.45 and a twelve month high of $28.35. The company's 50-day moving average is $22.20 and its 200-day moving average is $23.88. The company has a market capitalization of $3.83 billion, a P/E ratio of 9.76, a P/E/G ratio of 22.90 and a beta of 0.86.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $1.48. ACADIA Pharmaceuticals had a return on equity of 12.49% and a net margin of 36.49%.The business had revenue of $298.00 million during the quarter, compared to analysts' expectations of $292.54 million. During the same period in the prior year, the firm posted $0.86 EPS. ACADIA Pharmaceuticals's quarterly revenue was up 9.4% compared to the same quarter last year. As a group, equities analysts expect that ACADIA Pharmaceuticals Inc. will post 0.45 EPS for the current fiscal year.

Analyst Ratings Changes

ACAD has been the subject of a number of recent research reports. Wolfe Research initiated coverage on ACADIA Pharmaceuticals in a report on Monday, February 23rd. They issued an "outperform" rating and a $33.00 target price for the company. Royal Bank Of Canada dropped their target price on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Thursday, February 26th. Stifel Nicolaus dropped their target price on ACADIA Pharmaceuticals from $25.00 to $24.00 and set a "hold" rating for the company in a report on Thursday, February 26th. Citizens Jmp increased their target price on ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a "market outperform" rating in a report on Thursday, February 26th. Finally, JPMorgan Chase & Co. increased their target price on ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the stock an "overweight" rating in a report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $31.21.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Illinois Municipal Retirement Fund boosted its position in ACADIA Pharmaceuticals by 12.7% in the 1st quarter. Illinois Municipal Retirement Fund now owns 71,183 shares of the biopharmaceutical company's stock valued at $1,585,000 after buying an additional 7,996 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in ACADIA Pharmaceuticals by 30.6% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,923 shares of the biopharmaceutical company's stock valued at $288,000 after buying an additional 3,026 shares during the last quarter. Principal Financial Group Inc. boosted its position in ACADIA Pharmaceuticals by 3.1% in the 1st quarter. Principal Financial Group Inc. now owns 768,224 shares of the biopharmaceutical company's stock valued at $17,101,000 after buying an additional 22,868 shares during the last quarter. Fifth Third Bancorp boosted its position in ACADIA Pharmaceuticals by 5,053.5% in the 1st quarter. Fifth Third Bancorp now owns 31,694 shares of the biopharmaceutical company's stock valued at $706,000 after buying an additional 31,079 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its position in ACADIA Pharmaceuticals by 67.4% in the 1st quarter. Hsbc Holdings PLC now owns 44,008 shares of the biopharmaceutical company's stock valued at $977,000 after buying an additional 17,722 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.